Literature DB >> 9733884

Two novel adenovirus vector systems permitting regulated protein expression in gene transfer experiments.

M Molin1, M C Shoshan, K Ohman-Forslund, S Linder, G Akusjärvi.   

Abstract

Two new adenovirus vector systems based on the tetracycline-regulated Tet-ON- (Gossen, M., et al., Science 268:1766-1769, 1995) and the RU 486-regulated progesterone antagonist (Wang, Y., et al., Proc. Natl. Acad. Sci. USA 91:8180-8184, 1994)-induced gene expression systems are described. We show that both systems permit a tight control of chloramphenicol acetyltransferase reporter gene expression in a variety of cell types, with induction levels of approximately 1,800-fold (Tet-ON system) and 600-fold (RU 486-regulated system), respectively. A significant advantage of our vector systems is that reporter protein expression can be adjusted over a wide range by varying the amount of inducer. The Tet-ON system is also shown to permit an efficient control of reporter gene expression in mice.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9733884      PMCID: PMC110212     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  14 in total

1.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.

Authors:  M Gossen; H Bujard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

Review 2.  Expression of heterologous sequences in adenoviral vectors.

Authors:  K L Berkner
Journal:  Curr Top Microbiol Immunol       Date:  1992       Impact factor: 4.291

3.  Adenovirus E4 open reading frame 4 protein autoregulates E4 transcription by inhibiting E1A transactivation of the E4 promoter.

Authors:  M Bondesson; K Ohman; M Manervik; S Fan; G Akusjärvi
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

4.  Transduction of primitive human hematopoietic cells with recombinant adenovirus vectors.

Authors:  S J Neering; S F Hardy; D Minamoto; S K Spratt; C T Jordan
Journal:  Blood       Date:  1996-08-15       Impact factor: 22.113

5.  Adenovirus-mediated inducible gene expression through tetracycline-controllable transactivator with nuclear localization signal.

Authors:  Y Yoshida; H Hamada
Journal:  Biochem Biophys Res Commun       Date:  1997-01-13       Impact factor: 3.575

Review 6.  Gene therapy using adenoviral vectors.

Authors:  B C Trapnell; M Gorziglia
Journal:  Curr Opin Biotechnol       Date:  1994-12       Impact factor: 9.740

7.  Isolation of deletion and substitution mutants of adenovirus type 5.

Authors:  N Jones; T Shenk
Journal:  Cell       Date:  1978-01       Impact factor: 41.582

8.  Development of an adenovirus vector with tetracycline-regulatable human tumor necrosis factor alpha gene expression.

Authors:  S X Hu; W Ji; Y Zhou; C Logothetis; H J Xu
Journal:  Cancer Res       Date:  1997-08-15       Impact factor: 12.701

9.  A regulatory system for use in gene transfer.

Authors:  Y Wang; B W O'Malley; S Y Tsai; B W O'Malley
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

10.  Transcriptional activation by tetracyclines in mammalian cells.

Authors:  M Gossen; S Freundlieb; G Bender; G Müller; W Hillen; H Bujard
Journal:  Science       Date:  1995-06-23       Impact factor: 47.728

View more
  16 in total

1.  Overexpression of essential splicing factor ASF/SF2 blocks the temporal shift in adenovirus pre-mRNA splicing and reduces virus progeny formation.

Authors:  M Molin; G Akusjärvi
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

Review 2.  Regulatable gene expression systems for gene therapy applications: progress and future challenges.

Authors:  S Goverdhana; M Puntel; W Xiong; J M Zirger; C Barcia; J F Curtin; E B Soffer; S Mondkar; G D King; J Hu; S A Sciascia; M Candolfi; D S Greengold; P R Lowenstein; M G Castro
Journal:  Mol Ther       Date:  2005-08       Impact factor: 11.454

3.  Cellular splicing and transcription regulatory protein p32 represses adenovirus major late transcription and causes hyperphosphorylation of RNA polymerase II.

Authors:  Christina Ohrmalm; Göran Akusjärvi
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

Review 4.  Regulatable gene expression systems for gene therapy.

Authors:  Nuria Vilaboa; Richard Voellmy
Journal:  Curr Gene Ther       Date:  2006-08       Impact factor: 4.391

Review 5.  Methods for gene transfer to the central nervous system.

Authors:  Boris Kantor; Rachel M Bailey; Keon Wimberly; Sahana N Kalburgi; Steven J Gray
Journal:  Adv Genet       Date:  2014       Impact factor: 1.944

6.  Adenovirus vector designed for expression of toxic proteins.

Authors:  D Edholm; M Molin; E Bajak; G Akusjärvi
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

7.  ICP0, ICP4, or VP16 expressed from adenovirus vectors induces reactivation of latent herpes simplex virus type 1 in primary cultures of latently infected trigeminal ganglion cells.

Authors:  W P Halford; C D Kemp; J A Isler; D J Davido; P A Schaffer
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

8.  ERK signalling in metastatic human MDA-MB-231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation.

Authors:  M Seddighzadeh; J N Zhou; U Kronenwett; M C Shoshan; G Auer; M Sten-Linder; B Wiman; S Linder
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

9.  Establishment of an artificial beta-cell line expressing insulin under the control of doxycycline.

Authors:  Xin-Yu Qin; Kun-Tang Shen; Xin Zhang; Zhi-Hong Cheng; Xiang-Ru Xu; Ze-Guang Han
Journal:  World J Gastroenterol       Date:  2002-04       Impact factor: 5.742

10.  Rescue and production of vaccine and therapeutic adenovirus vectors expressing inhibitory transgenes.

Authors:  Jason G D Gall; Alena Lizonova; Damodar EttyReddy; Duncan McVey; Mohammed Zuber; Imre Kovesdi; Barbara Aughtman; C Richter King; Douglas E Brough
Journal:  Mol Biotechnol       Date:  2007-03       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.